Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Profit After Tax (2016 - 2025)

Altimmune (ALT) has disclosed Profit After Tax for 16 consecutive years, with -$27.4 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 18.02% to -$27.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.1 million through Dec 2025, up 7.33% year-over-year, with the annual reading at -$88.1 million for FY2025, 7.33% up from the prior year.
  • Profit After Tax for Q4 2025 was -$27.4 million at Altimmune, down from -$19.0 million in the prior quarter.
  • The five-year high for Profit After Tax was -$14.9 million in Q1 2021, with the low at -$33.5 million in Q3 2021.
  • Average Profit After Tax over 5 years is -$22.7 million, with a median of -$22.5 million recorded in 2024.
  • The sharpest move saw Profit After Tax plummeted 282.54% in 2021, then increased 29.82% in 2022.
  • Over 5 years, Profit After Tax stood at -$23.9 million in 2021, then rose by 9.33% to -$21.7 million in 2022, then tumbled by 46.08% to -$31.6 million in 2023, then grew by 26.74% to -$23.2 million in 2024, then fell by 18.02% to -$27.4 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$27.4 million, -$19.0 million, and -$22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.